KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) Enterprise Value (2018 - 2025)

Historic Enterprise Value for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to -$92.4 million.

  • Esperion Therapeutics' Enterprise Value rose 3611.88% to -$92.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$92.4 million, marking a year-over-year increase of 3611.88%. This contributed to the annual value of -$144.8 million for FY2024, which is 7600.55% down from last year.
  • Esperion Therapeutics' Enterprise Value amounted to -$92.4 million in Q3 2025, which was up 3611.88% from -$86.1 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year Enterprise Value high stood at -$82.2 million for Q4 2023, and its period low was -$259.3 million during Q4 2021.
  • Moreover, its 5-year median value for Enterprise Value was -$162.3 million (2023), whereas its average is -$160.9 million.
  • In the last 5 years, Esperion Therapeutics' Enterprise Value crashed by 8263.47% in 2022 and then surged by 5453.82% in 2025.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Enterprise Value stood at -$259.3 million in 2021, then soared by 35.66% to -$166.9 million in 2022, then soared by 50.71% to -$82.2 million in 2023, then tumbled by 76.01% to -$144.8 million in 2024, then surged by 36.14% to -$92.4 million in 2025.
  • Its Enterprise Value was -$92.4 million in Q3 2025, compared to -$86.1 million in Q2 2025 and -$114.6 million in Q1 2025.